SG178743A1 - Smoothened polypeptides and methods of use - Google Patents

Smoothened polypeptides and methods of use Download PDF

Info

Publication number
SG178743A1
SG178743A1 SG2012007373A SG2012007373A SG178743A1 SG 178743 A1 SG178743 A1 SG 178743A1 SG 2012007373 A SG2012007373 A SG 2012007373A SG 2012007373 A SG2012007373 A SG 2012007373A SG 178743 A1 SG178743 A1 SG 178743A1
Authority
SG
Singapore
Prior art keywords
fatty acid
seq
peptidomimetic
misc
leu
Prior art date
Application number
SG2012007373A
Other languages
English (en)
Inventor
Tarasova Nadya
Dean Michael
Lou Hong
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of SG178743A1 publication Critical patent/SG178743A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2012007373A 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use SG178743A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85542206P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
SG178743A1 true SG178743A1 (en) 2012-03-29

Family

ID=39492945

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012007373A SG178743A1 (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use
SG2011080447A SG175691A1 (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011080447A SG175691A1 (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Country Status (13)

Country Link
US (3) US8198402B2 (enExample)
EP (2) EP2431388A1 (enExample)
JP (3) JP5399255B2 (enExample)
KR (1) KR101563010B1 (enExample)
CN (2) CN103435694A (enExample)
AU (1) AU2007329678A1 (enExample)
CA (1) CA2667821A1 (enExample)
MY (2) MY181496A (enExample)
NZ (1) NZ576467A (enExample)
PH (1) PH12013502425B1 (enExample)
SG (2) SG178743A1 (enExample)
WO (1) WO2008070357A2 (enExample)
ZA (1) ZA200902894B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY181496A (en) * 2006-10-31 2020-12-23 Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
CA2710377A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
AU2013352256A1 (en) 2012-11-29 2015-06-18 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101723649B1 (ko) * 2014-10-23 2017-04-06 서울대학교산학협력단 신규한 펩티드 화합물, 이의 생산 방법, 및 이의 용도
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
JP6889432B2 (ja) * 2016-04-28 2021-06-18 学校法人甲南学園 樹脂固定ペプチド
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CN110520144B (zh) * 2017-02-19 2024-04-05 本-古里安大学B.G.内盖夫技术和应用公司 肽激酶抑制剂及其使用方法
CN108644311B (zh) * 2018-05-22 2019-09-06 东北大学 一种基于硬化立方刚度吸振器实现方法及吸振器

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
AU8380898A (en) * 1997-07-01 1999-01-25 Ingham, Philip W Vertebrate smoothened gene, gene products, and uses related thereto
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
AU2001257169C1 (en) * 2000-04-21 2011-06-16 Tufts Medical Center, Inc. G-protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
EA007339B1 (ru) * 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
JP2007527503A (ja) * 2003-06-17 2007-09-27 プロノタ・エヌブイ ペプチドコンボ及びそれらの使用
CA2586344C (en) 2004-11-04 2013-05-28 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2007134272A2 (en) * 2006-05-12 2007-11-22 Janssen Pharmaceutica N.V. Humanized models via targeted mtagenesis with zinc finger nuclease
MY181496A (en) * 2006-10-31 2020-12-23 Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services Smoothened polypeptides and methods of use

Also Published As

Publication number Publication date
SG175691A1 (en) 2011-11-28
JP2013255500A (ja) 2013-12-26
WO2008070357A3 (en) 2009-02-26
KR20090084839A (ko) 2009-08-05
WO2008070357A2 (en) 2008-06-12
CA2667821A1 (en) 2008-06-12
CN101616931A (zh) 2009-12-30
NZ576467A (en) 2012-03-30
MY149170A (en) 2013-07-31
JP2015180630A (ja) 2015-10-15
HK1137031A1 (en) 2010-07-16
PH12013502425A1 (en) 2014-10-27
JP5739484B2 (ja) 2015-06-24
KR101563010B1 (ko) 2015-10-26
US20100093625A1 (en) 2010-04-15
US8546524B2 (en) 2013-10-01
US20120282196A1 (en) 2012-11-08
JP2010508305A (ja) 2010-03-18
JP5399255B2 (ja) 2014-01-29
WO2008070357A9 (en) 2008-08-14
PH12013502425B1 (en) 2014-10-27
ZA200902894B (en) 2010-04-28
AU2007329678A1 (en) 2008-06-12
US8198402B2 (en) 2012-06-12
EP2078036A2 (en) 2009-07-15
US20130316957A1 (en) 2013-11-28
MY181496A (en) 2020-12-23
CN103435694A (zh) 2013-12-11
CN101616931B (zh) 2013-08-21
EP2431388A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
US8546524B2 (en) Smoothened polypeptides and methods of use
JP6267644B2 (ja) 抗ｃｄ２２キメラ抗原受容体
JP2021191265A (ja) Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体
BR112015009003B1 (pt) Receptores de antígeno quiméricos que se ligam especificamente a cd22, ácido nucleico, vetor de expressão recombinante, microrganismo transgênico, composição farmacêutica, e uso dos mesmos
Di Maro et al. Exploring the N-terminal region of CXC motif chemokine 12 (CXCL12): identification of plasma-stable cyclic peptides as novel, potent CXC chemokine receptor type 4 (CXCR4) antagonists
US9890197B2 (en) RHAMM binding peptides
EP2687537B1 (en) Polypeptide drug against hepatitis b virus x protein
JP5769420B2 (ja) Ｎｃａｍ由来の新規ペプチド（ｆｇｌｓ）
HK1191961A (en) Smoothened polypeptides and methods of use
HK1137031B (en) Smoothened polypeptides and methods of use
Haslach Rational drug design approaches targeting the mouse and human melanocortin receptors